JP2004517630A - Src−2発現のアンチセンスモジュレーション - Google Patents

Src−2発現のアンチセンスモジュレーション Download PDF

Info

Publication number
JP2004517630A
JP2004517630A JP2002558463A JP2002558463A JP2004517630A JP 2004517630 A JP2004517630 A JP 2004517630A JP 2002558463 A JP2002558463 A JP 2002558463A JP 2002558463 A JP2002558463 A JP 2002558463A JP 2004517630 A JP2004517630 A JP 2004517630A
Authority
JP
Japan
Prior art keywords
acid
antisense
src
oligonucleotide
antisense compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002558463A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004517630A5 (https=
Inventor
ベネット,シー・フランク
カウサート,レックス・エム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionis Pharmaceuticals Inc
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Publication of JP2004517630A publication Critical patent/JP2004517630A/ja
Publication of JP2004517630A5 publication Critical patent/JP2004517630A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3212'-O-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/33Chemical structure of the base
    • C12N2310/334Modified C
    • C12N2310/33415-Methylcytosine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/34Spatial arrangement of the modifications
    • C12N2310/341Gapmers, i.e. of the type ===---===
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/34Spatial arrangement of the modifications
    • C12N2310/346Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
JP2002558463A 2000-11-27 2001-11-26 Src−2発現のアンチセンスモジュレーション Withdrawn JP2004517630A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/723,535 US6355483B1 (en) 2000-11-27 2000-11-27 Antisenses inhibition of SRC-2 expression
PCT/US2001/044216 WO2002057409A2 (en) 2000-11-27 2001-11-26 Antisense modulation of src-2 expression

Publications (2)

Publication Number Publication Date
JP2004517630A true JP2004517630A (ja) 2004-06-17
JP2004517630A5 JP2004517630A5 (https=) 2005-05-19

Family

ID=24906673

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002558463A Withdrawn JP2004517630A (ja) 2000-11-27 2001-11-26 Src−2発現のアンチセンスモジュレーション

Country Status (5)

Country Link
US (1) US6355483B1 (https=)
EP (1) EP1346065A2 (https=)
JP (1) JP2004517630A (https=)
AU (1) AU2002245030A1 (https=)
WO (1) WO2002057409A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355483B1 (en) * 2000-11-27 2002-03-12 Isis Pharmaceuticals, Inc. Antisenses inhibition of SRC-2 expression

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5734039A (en) * 1994-09-15 1998-03-31 Thomas Jefferson University Antisense oligonucleotides targeting cooperating oncogenes
US6268173B1 (en) * 1996-07-12 2001-07-31 Institut Natural De La Sante Et La Recherche Medicale Polynucleotide encoding transcriptional intermediary factor-2
WO1998056806A1 (en) * 1997-06-12 1998-12-17 The Regents Of The University Of California A TRANSCRIPTION FACTOR COACTIVATOR PROTEIN, p/CIP
US5951455A (en) * 1998-12-04 1999-09-14 Isis Pharmaceuticals, Inc. Antisense modulation of G-alpha-11 expression
US6355483B1 (en) * 2000-11-27 2002-03-12 Isis Pharmaceuticals, Inc. Antisenses inhibition of SRC-2 expression

Also Published As

Publication number Publication date
WO2002057409A3 (en) 2002-09-12
AU2002245030A1 (en) 2002-07-30
EP1346065A2 (en) 2003-09-24
WO2002057409A2 (en) 2002-07-25
US6355483B1 (en) 2002-03-12

Similar Documents

Publication Publication Date Title
JP4054192B2 (ja) Ptp1b発現のアンチセンス阻害
JP4397585B2 (ja) クラスタリン発現のアンチセンスモジュレーション
JP2003505351A (ja) Mapキナーゼキナーゼ6発現のアンチセンスモジュレーション
JP2003520241A (ja) Mekk2発現のアンチセンスモジュレーション
JP2004509619A (ja) Flip−c発現のアンチセンスモジュレーション
JP2003520584A (ja) カスパーゼ3発現のアンチセンスモジュレーション
JP2003503048A (ja) Ship−2発現のアンチセンスモジュレーション
JP2003520586A (ja) Smad7発現のアンチセンスモジュレーション
JP2003505027A (ja) Pi3キナーゼp110デルタ発現のアンチセンスモジュレーション
JP2003520042A (ja) 誘導性一酸化窒素シンターゼ発現のアンチセンスモジュレーション
JP2003505062A (ja) Pten発現のアンチセンスモジュレーション
AU768799B2 (en) Antisense modulation of integrin-linked kinase expression
JP2003505063A (ja) Mekk5発現のアンチセンスモジュレーション
JP2003520585A (ja) ペルオキシソーム増殖因子−活性化受容体ガンマ発現のアンチセンスモジュレーション発現のアンチセンスモジュレーション
JP2003508089A (ja) PI3キナーゼp110ベータ発現のアンチセンスモジュレーション
JP2003505092A (ja) Shp−2発現のアンチセンスモジュレーション
JP2003520051A (ja) Pepck−サイトゾル発現のアンチセンスモジュレーション
JP2003518928A (ja) Akt−3発現のアンチセンスモジュレーション
JP2003505026A (ja) 肝臓グリコーゲンホスホリラーゼ発現のアンチセンスモジュレーション
JP2003525058A (ja) E2f転写因子1発現のアンチセンスモジュレーション
JP2003531630A (ja) Dna結合阻害剤−1発現のアンチセンスモジュレーション
JP2004503232A (ja) C/EBPβ発現のアンチセンスモジュレーション
JP2005525829A (ja) 糖質コルチコイド受容体発現のアンチセンス調節
JP2003527085A (ja) Pepck−ミトコンドリア発現のアンチセンスモジュレーション
JP2003512079A (ja) タンパク質キナーゼc−シータ発現のアンチセンスモジュレーション

Legal Events

Date Code Title Description
A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20050204